Last reviewed · How we verify
MOVICOL
At a glance
| Generic name | MOVICOL |
|---|---|
| Also known as | Macrogol (PEG) 3350, sodium chloride, sodium bicarbonate, potassium chloride, acesulfame potassium |
| Sponsor | Norgine |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effects of Changing Intestinal Transit Time on Gut Microbial Composition and Metabolism (NA)
- Colon Capsule Endoscopy in Patients With Colonic Diverticulitis (NA)
- Polyethylene Glycol Versus Lactulose on Hepatic Encephalopathy in Patients With Cirrhosis;(PEGHE Trial) (PHASE4)
- Study to Investigate Prucalopride vs. Polyethylene Glycol 3350 on Colon Activity (PHASE4)
- Effectiveness of PLENVU in the General Screening Population and Patients With IBD
- Study of Different Endoscopic Preparations Used in Pediatric Colonoscopy
- Maintenance Treatment for Children With Constipation (NA)
- Dose-Finding Trial of Polyethylene Glycol 3350 Laxative Plus Electrolytes for the Treatment of Constipation (Protocol P07515) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MOVICOL CI brief — competitive landscape report
- MOVICOL updates RSS · CI watch RSS
- Norgine portfolio CI